Community Acquired Pneumonia - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H1 2019’, provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia

- The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects

- The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Basilea Pharmaceutica Ltd

Biotest AG

InflaRx NV

ioGenetics Inc

Iterum Therapeutics Plc

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck ...

Basilea Pharmaceutica Ltd

Biotest AG

InflaRx NV

ioGenetics Inc

Iterum Therapeutics Plc

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Nabriva Therapeutics Plc

Paratek Pharmaceuticals Inc

ProThera Biologics Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

Tetraphase Pharmaceuticals Inc

Wockhardt Ltd

Table of Contents

Table of Contents

Introduction

Community Acquired Pneumonia – Overview

Community Acquired Pneumonia – Therapeutics Development

Community Acquired Pneumonia – Therapeutics Assessment

Community Acquired Pneumonia – Companies Involved in Therapeutics ...

Table of Contents

Introduction

Community Acquired Pneumonia – Overview

Community Acquired Pneumonia – Therapeutics Development

Community Acquired Pneumonia – Therapeutics Assessment

Community Acquired Pneumonia – Companies Involved in Therapeutics Development

Community Acquired Pneumonia – Drug Profiles

Community Acquired Pneumonia – Dormant Projects

Community Acquired Pneumonia – Discontinued Products

Community Acquired Pneumonia – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Community Acquired Pneumonia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Community Acquired Pneumonia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Community Acquired Pneumonia – Pipeline by Basilea Pharmaceutica Ltd, H1 2019

Community Acquired Pneumonia – Pipeline by Biotest AG, H1 2019

Community Acquired Pneumonia – Pipeline by InflaRx NV, H1 2019

Community Acquired Pneumonia – Pipeline by ioGenetics Inc, H1 2019

Community Acquired Pneumonia – Pipeline by Iterum Therapeutics Plc, H1 2019

Community Acquired Pneumonia – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019

Community Acquired Pneumonia – Pipeline by Meiji Seika Pharma Co Ltd, H1 2019

Community Acquired Pneumonia – Pipeline by Melinta Therapeutics Inc, H1 2019

Community Acquired Pneumonia – Pipeline by Merck & Co Inc, H1 2019

Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics Plc, H1 2019

Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc, H1 2019

Community Acquired Pneumonia – Pipeline by ProThera Biologics Inc, H1 2019

Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd, H1 2019

Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Community Acquired Pneumonia – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019

Community Acquired Pneumonia – Pipeline by Wockhardt Ltd, H1 2019

Community Acquired Pneumonia – Dormant Projects, H1 2019

Community Acquired Pneumonia – Dormant Projects, H1 2019 (Contd..1), H1 2019

Community Acquired Pneumonia – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Community Acquired Pneumonia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Community Acquired Pneumonia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports